Table 1.
Demographic and clinical variables.
| Variable | NVAFa cases (N = 103) | NSRb controls (N = 48) | P |
|---|---|---|---|
| Female, n (%) | 31 (30) | 21 (44) | 0.1030 |
| Age, years (mean ± SDc) | 61.9 ± 14.8 | 62.3 ± 14.7 | 0.8749 |
| 65–74years, n (%) | 23 (22) | 10 (21) | 0.8358 |
| ≥75, n (%) | 19 (19) | 11 (23) | 0.5215 |
| Body mass index (mean ± SD) | 30.9 ± 6.9 | 30.1 ± 7.2 | 0.4689 |
| Congestive heart failure, n (%) | 30 (29) | 8 (17) | 0.0918 |
| Hypertension, n (%) | 59 (57) | 17 (35) | 0.0119 |
| Diabetes mellitus, n (%) | 15 (15) | 10 (21) | 0.3419 |
| Stroke/TIA prior, n (%) | 12 (12) | 4 (8) | 0.5296 |
| Vascular diseases, n (%) | 19 (19) | 5 (10) | 0.1946 |
| CHADS2, mean ± SD | 1.43 ± 1.4 | 1.12 ± 1.5 | 0.2329 |
| score 0, n (%) | 35 (34) | 25 (52) | |
| score 1, n (%) | 26 (25) | 8 (17) | |
| score ≥ 2, n (%) | 42 (41) | 15 (31) | |
| CHA2DS2-VASc, mean ± SD | 2.34 ± 2.0 | 1.87 ± 1.9 | 0.1791 |
| score 0, n (%) | 23 (22) | 12 (25) | |
| score 1, n (%) | 19 (19) | 13 (27) | |
| score ≥ 2, n (%) | 61 (59) | 23 (48) | |
| Warfarin therapy, n (%) | 79 (77) | 1 (2) | <0.0001 |
| Statin therapy, n (%) | 27 (26) | 9 (19) | 0.3088 |
a
NVAF – non-valvular atrial fibrillation.
b
NSR – normal sinus rhythm.
c
SD – standard deviation.